Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A110TG | ISIN: IL0011316309 | Ticker-Symbol: M8W
Frankfurt
28.03.25
09:15 Uhr
15,500 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDIWOUND LTD Chart 1 Jahr
5-Tage-Chart
MEDIWOUND LTD 5-Tage-Chart
RealtimeGeldBriefZeit
13,90014,40020:04

Aktuelle News zur MEDIWOUND Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MEDIWOUND Aktie jetzt für 0€ handeln
22.03.Analysts Offer Predictions for MediWound FY2029 Earnings1
19.03.MediWound files to sell $125M mixed securities shelf, 1.26M ordinary shares for holders2
19.03.MediWound Ltd. Q4 Loss Increases, But Beats Estimates2
19.03.MediWound Ltd. - S-8, Securities to be offered to employees in employee benefit plans-
19.03.MediWound Ltd. - 20-F, Annual and transition report of foreign private issuers3
19.03.MediWound GAAP EPS of -$0.36 beats by $0.23, revenue of $5.84M beats by $0.09M1
19.03.MediWound Ltd.: MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update395Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue...
► Artikel lesen
19.03.MediWound Ltd. - 6-K, Report of foreign issuer-
18.03.MediWound Q4 2024 Earnings Preview1
28.02.Craig-Hallum sets $39 target on MediWound stock with buy rating1
12.02.MediWound stock climbs 4% on Phase 3 study initiation1
12.02.MediWound Ltd.: MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx for Treatment of Venous Leg Ulcers164Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected...
► Artikel lesen
12.02.MediWound Ltd. - 6-K, Report of foreign issuer-
08.01.MediWound Ltd. - 6-K, Report of foreign issuer5
16.12.24MediWound Ltd. - 6-K, Report of foreign issuer1
26.11.24MediWound Ltd. Q3 Loss Increases, Misses Estimates1
26.11.24MediWound GAAP EPS of -$0.98 misses by $0.53, revenue of $4.35M misses by $1.66M3
26.11.24MediWound Ltd.: MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update323EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric Use $25 Million Financing and €16.25 Million...
► Artikel lesen
26.11.24MediWound Ltd. - 6-K, Report of foreign issuer-
25.11.24MediWound Q3 2024 Earnings Preview1
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1